Influence of HMG-CoA Reductase Inhibitor to Virological Response of Peginterferon/Ribavirin Combination Therapy in Chronic Hepatitis C

Acta Hepatologica Japonica - Japan
doi 10.2957/kanzo.49.22
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Japan Society of Hepatology

Related search

Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C

Internal Medicine
Internal MedicineMedicine
2007English

The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C

Gastroenterology
HepatologyGastroenterology
2011English

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Eastern Mediterranean Health Journal
Medicine
2011English

Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers

Circulation Journal
MedicineCardiovascular MedicineCardiology
2010English

Virological Response to Treatment With Peginterferon Alfa-2a in Adolescents With Chronic Hepatitis B.

Acta Biochimica Polonica
BiochemistryGeneticsMolecular Biology
2012English

Effects of Combined Therapy Using HMG-CoA Reductase Inhibitor and Colestimide on Refractory Hypercholesterolemia

The Journal of Japan Atherosclerosis Society
2002English

Cost Effectiveness of Interferon or Peginterferon With Ribavirin for Histologically Mild Chronic Hepatitis C

Gut
Gastroenterology
2006English

Non-Invasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir With Pegylated Interferon and Ribavirin for Chronic Hepatitis C

Antiviral Therapy
Infectious DiseasesPharmacology
2014English

Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Associated With Thyroid Dysfunction

Acta Hepatologica Japonica
Hepatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy